{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 39,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes specific clinical metrics (ORR, mPFS, mOS) comparing patients above and below the Minimal Efficacious Concentration (MEC).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/14",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.75
      },
      "kind": "disclaimer",
      "text": "Taxol PL Reference ID: 2939751. DLT = dose-limiting toxicity, mOS = median overall survival, mPFS = median progression free survival, ORR = overall response rate. RP2D = recommended P2 dose.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6c6d077-ead8-47f3-a34c-b5db22176ef6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "list",
      "text": "Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile. Exposure-response relationship identified by unsupervised computer analysis. Minimal efficacious concentration (MEC) identified.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4358c970-a60c-4ac8-a8a3-78f472b632b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.023
      },
      "kind": "table",
      "text": "Efficacy Data for Patients Receiving 10 mg/kg and 15 mg/kg of Batiraxcept & Paclitaxel. Columns: >MEC (N=10), <MEC (N=9). Rows: ORR (50% vs 22%), mPFS (7.5 vs 2.8), mOS (19.0 vs 8.7).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bccb4c40-c76e-4cb9-aa71-61c629dd481a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "title",
      "text": "Modeling Identified RP2D of 15 mg/kg for PROC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7065b5cd-1988-430e-b646-181fd5d44fff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f75d887a-0428-4e92-b116-6ae184aa8f8c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "5f3f6ab7-cff1-4a24-af92-6b326c014ddd",
      "evidence": "table/data: Efficacy Data for Patients Receiving 10 mg/kg and 15 mg/kg of Batiraxcept & Paclitaxel. Columns: >MEC (N=10), <MEC (N=9). Rows: ORR (50% vs 22%), mPFS (7.5 vs 2.8), mOS (19.0 vs 8.7).",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 12,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "ca889fd8-550d-4690-bdfd-ec18eba75312",
      "evidence": "The document presents promising results for Batiraxcept in PROC and highlights its potential for expansion into other indications",
      "position": 1,
      "objective": "Can Batiraxcept provide a quick win in PROC and a big bet for future growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}